The efficacy and safety of strontium ranelate in the treatment of male osteoporosis: a prospective multicentre, international, double-blind, placebo-controlled study with a treatment duration of 2 years and the main study analysis after 1 year.

Trial Profile

The efficacy and safety of strontium ranelate in the treatment of male osteoporosis: a prospective multicentre, international, double-blind, placebo-controlled study with a treatment duration of 2 years and the main study analysis after 1 year.

Completed
Phase of Trial: Phase III

Latest Information Update: 16 Sep 2014

At a glance

  • Drugs Strontium ranelate (Primary)
  • Indications Male osteoporosis
  • Focus Biomarker; Registrational; Therapeutic Use
  • Acronyms MALEO
  • Most Recent Events

    • 24 Mar 2012 Results assessing bone turnover markers presented at the 2012 IOF World Congress on Osteoporosis and 11th European Congress on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis.
    • 24 Mar 2012 Primary efficacy analysis presented at the 2012 IOF World Congress on Osteoporosis and 11th European Congress on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis.
    • 09 Nov 2011 Results presented at the 75th Annual Scientific Meeting of the American College of Rheumatology and the 46th Annual Meeting of the Association of Rheumatology and Health Professionals.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top